Akoya Biosciences Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 205

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $242M

Akoya Biosciences General Information

Description

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Campus Drive
  • 6th Floor
  • Marlborough, MA 01752
  • United States
Primary Industry
Other Pharmaceuticals and Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 100 Campus Drive
  • 6th Floor
  • Marlborough, MA 01752
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akoya Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 08-Jul-2025 $242M Completed Generating Revenue
8. IPO 16-Apr-2021 Completed Generating Revenue
7. Debt - General 01-Oct-2020 Completed Generating Revenue
6. Debt - PPP 27-Apr-2020 Completed Generating Revenue
5. Later Stage VC (Series D) 27-Sep-2019 Completed Generating Revenue
4. Later Stage VC (Series C) 02-Oct-2018 Completed Product Development
3. Early Stage VC (Series B) 14-Jul-2017 Completed Product Development
2. Early Stage VC (Series A) 13-Nov-2015 $1.25M $1.25M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Akoya Biosciences’s complete valuation and funding history, request access »

Akoya Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 13,715,330 $0.000010 8% $0.66 $0.66 1x $0.66 22.26%
Series A 5,013,333 $0.000010 8% $0.25 $0.25 1x $0.25 8.13%
To view Akoya Biosciences’s complete cap table history, request access »

Akoya Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on trans
Other Pharmaceuticals and Biotechnology
Marlborough, MA
205 As of 2024

Pleasanton, CA
 

Seraing, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akoya Biosciences Competitors (15)

One of Akoya Biosciences’s 15 competitors is 10x Genomics, a Formerly VC-backed company based in Pleasanton, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
10x Genomics Formerly VC-backed Pleasanton, CA
Diagenode Formerly VC-backed Seraing, Belgium
Flagship Biosciences Formerly VC-backed Broomfield, CO
NorthStar (Pharmaceuticals) Venture Capital-Backed Beloit, WI
Standard BioTools Formerly VC-backed Boston, MA
You’re viewing 5 of 15 competitors. Get the full list »

Akoya Biosciences Patents

Akoya Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024404390-A1 Spatially resolved cyclic multiplexed detection of nucleic acids and proteins in tissue Pending 21-Dec-2023
EP-4829044-A1 Spatially resolved cyclic multiplexed detection of nucleic acids and proteins in tissue Pending 21-Dec-2023
US-20250207180-A1 Spatially resolved cyclic multiplexed detection of nucleic acids and proteins in tissue Pending 21-Dec-2023
WO-2025137702-A1 Spatially resolved cyclic multiplexed detection of nucleic acids and proteins in tissue Inactive 21-Dec-2023
EP-4445196-A1 Surface sensing in automated sample analysis Pending 10-Dec-2021 G02B7/28
To view Akoya Biosciences’s complete patent history, request access »

Akoya Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akoya Biosciences Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agilent Technologies Corporation Minority
Innovatus Capital Partners Asset Manager Minority
Leland Stanford Junior University University Minority
Angel (individual) Minority
Piper Sandler Investment Bank Minority
You’re viewing 5 of 8 investors. Get the full list »

Akoya Biosciences Investments & Acquisitions (2)

Akoya Biosciences’s most recent deal was a Corporate Asset Purchase with PerkinElmer (Phenoptics portfolio). The deal was made on 31-Oct-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PerkinElmer (Phenoptics portfolio) 31-Oct-2018 Corporate Asset Purchase Buildings and Property
PerkinElmer (Quantitative Pathology Solutions Division) 28-Sep-2018 Merger/Acquisition Laboratory Services (Healthcare)
To view Akoya Biosciences’s complete investments and acquisitions history, request access »

Akoya Biosciences ESG

Risk Overview

Risk Rating

Updated April, 30, 2025

37.39 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Akoya Biosciences’s complete esg history, request access »

Akoya Biosciences FAQs

  • When was Akoya Biosciences founded?

    Akoya Biosciences was founded in 2015.

  • Where is Akoya Biosciences headquartered?

    Akoya Biosciences is headquartered in Marlborough, MA.

  • What is the size of Akoya Biosciences?

    Akoya Biosciences has 205 total employees.

  • What industry is Akoya Biosciences in?

    Akoya Biosciences’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Akoya Biosciences a private or public company?

    Akoya Biosciences is a Private company.

  • What is the current valuation of Akoya Biosciences?

    The current valuation of Akoya Biosciences is .

  • What is Akoya Biosciences’s current revenue?

    The current revenue for Akoya Biosciences is .

  • How much funding has Akoya Biosciences raised over time?

    Akoya Biosciences has raised $256M.

  • Who are Akoya Biosciences’s investors?

    Agilent Technologies, Innovatus Capital Partners, Leland Stanford Junior University, , and Piper Sandler are 5 of 8 investors who have invested in Akoya Biosciences.

  • Who are Akoya Biosciences’s competitors?

    10x Genomics, Diagenode, Flagship Biosciences, NorthStar (Pharmaceuticals), and Standard BioTools are some of the 15 competitors of Akoya Biosciences.

  • When was Akoya Biosciences acquired?

    Akoya Biosciences was acquired on 08-Jul-2025.

  • Who acquired Akoya Biosciences?

    Akoya Biosciences was acquired by Quanterix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process